###begin article-title 0
###xml 16 21 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
NFAT5 Regulates HIV-1 in Primary Monocytes via a Highly Conserved Long Terminal Repeat Site
###end article-title 0
###begin p 1
###xml 14 19 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 231 236 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 289 294 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 810 815 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 817 822 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 992 997 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1054 1059 <span type="species:ncbi:9606">human</span>
###xml 1259 1264 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1422 1427 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To replicate, HIV-1 capitalizes on endogenous cellular activation pathways resulting in recruitment of key host transcription factors to its viral enhancer. RNA interference has been a powerful tool for blocking key checkpoints in HIV-1 entry into cells. Here we apply RNA interference to HIV-1 transcription in primary macrophages, a major reservoir of the virus, and specifically target the transcription factor NFAT5 (nuclear factor of activated T cells 5), which is the most evolutionarily divergent NFAT protein. By molecularly cloning and sequencing isolates from multiple viral subtypes, and performing DNase I footprinting, electrophoretic mobility shift, and promoter mutagenesis transfection assays, we demonstrate that NFAT5 functionally interacts with a specific enhancer binding site conserved in HIV-1, HIV-2, and multiple simian immunodeficiency viruses. Using small interfering RNA to ablate expression of endogenous NFAT5 protein, we show that the replication of three major HIV-1 viral subtypes (B, C, and E) is dependent upon NFAT5 in human primary differentiated macrophages. Our results define a novel host factor-viral enhancer interaction that reveals a new regulatory role for NFAT5 and defines a functional DNA motif conserved across HIV-1 subtypes and representative simian immunodeficiency viruses. Inhibition of the NFAT5-LTR interaction may thus present a novel therapeutic target to suppress HIV-1 replication and progression of AIDS.
###end p 1
###begin title 2
Synopsis
###end title 2
###begin p 3
###xml 225 230 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 236 246 <span type="species:ncbi:11676">AIDS virus</span>
###xml 457 462 <span type="species:ncbi:9606">human</span>
###xml 565 570 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 633 638 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 739 744 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 767 772 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 787 816 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
###xml 971 974 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
To replicate, viruses exploit the cellular machinery of infected cells in their hosts. Macrophages, blood cells involved in the body's defense against pathogens, are resistant to the toxic effects of certain viruses, such as HIV-1, the AIDS virus. The drawback, however, is that macrophages become an avenue through which viruses can spread to other tissues and organs of the body. Here, Ranjbar, Tsytsykova, and colleagues have identified a new role for a human protein, nuclear factor of activated T cells 5 (NFAT5), as a host factor important for replication of HIV-1 in macrophages. The binding site for NFAT5 on a region of the HIV-1 DNA critical for its replication, the long terminal repeat, is the same across multiple subtypes of HIV-1 and the related virus HIV-2, and even the simian immunodeficiency virus; thus, disrupting the interaction between NFAT5 and the long terminal repeat provides a potential means of inhibiting replication of multiple versions of HIV.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 97 98 97 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b001">1</xref>
###xml 99 100 99 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b003">3</xref>
###xml 116 117 116 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b004">4</xref>
###xml 118 119 118 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b007">7</xref>
###xml 271 272 271 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b003">3</xref>
###xml 288 289 288 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b007">7</xref>
###xml 290 292 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b010">10</xref>
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b011">11</xref>
###xml 671 672 671 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b007">7</xref>
###xml 673 675 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b012">12</xref>
###xml 90 95 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 199 204 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 254 259 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 335 340 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 362 367 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 494 499 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 528 533 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The monocyte/macrophage lineage and dendritic cells are the first cells to be infected by HIV-1 [1-3] (reviewed in [4-7]). Monocytes/macrophages are relatively resistant to the cytopathic effects of HIV-1 and thus can serve as a reservoir for persistent HIV-1 infection [3] (reviewed in [7-10]). Furthermore, based on experiments with HIV-1 subtype B, the first HIV-1 subtype identified [11], it has been suggested that signal transduction pathways and transcription factors acting to modulate HIV-1 gene expression through the HIV-1 long terminal repeat (LTR) enhancer region are distinct in the monocyte/macrophage lineage and dendritic cells as compared with T cells [7,12].
###end p 5
###begin p 6
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b013">13</xref>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b014">14</xref>
###xml 450 452 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b018">18</xref>
###xml 591 593 591 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b014">14</xref>
###xml 594 596 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b019">19</xref>
###xml 597 599 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b021">21</xref>
###xml 755 757 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b022">22</xref>
###xml 758 760 750 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b023">23</xref>
###xml 776 778 768 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b012">12</xref>
###xml 779 781 771 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b024">24</xref>
###xml 782 784 774 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b025">25</xref>
###xml 959 961 939 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b022">22</xref>
###xml 1085 1087 1065 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b026">26</xref>
###xml 1088 1090 1068 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b032">32</xref>
###xml 1216 1218 1192 1194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b033">33</xref>
###xml 1219 1221 1195 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b035">35</xref>
###xml 38 43 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 193 198 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 293 298 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 340 345 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 700 705 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 872 877 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A critical step in the replication of HIV-1 is the transcription of viral genes following integration of viral DNA into the genome of the host cell (reviewed in [13]). However, the majority of HIV-1 gene transcription studies have been performed using isolates of subtype B, although multiple HIV-1 subtypes have a major role in the global HIV-1 pandemic, and each subtype has a distinct sequence of transcription factor binding sites in its LTR [14-18]. Differences in the number and arrangement of these activator binding sites influence subtype-specific expression of the virus in vitro [14,19-21]. The ubiquitous transcription factor nuclear factor kappaB (NF-kappaB) has long been implicated in HIV-1 viral gene transcription in multiple cell types [22,23] (reviewed in [12,24,25]). Although the NF-kappaB motifs within the core kappaB enhancer/basal promoter of the HIV-1 subtype B LTR are canonical binding sites for the NF-kappaB p50/p65 heterodimer [22], they are also recognized by the calcineurin-dependent proteins of the nuclear factor of activated T cells (NFAT) family [26-32], which shares a structurally conserved DNA-binding motif with the NF-kappaB proteins, the rel homology region (reviewed in [33-35]).
###end p 6
###begin p 7
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b026">26</xref>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b028">28</xref>
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b030">30</xref>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b036">36</xref>
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b037">37</xref>
###xml 412 414 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b033">33</xref>
###xml 415 417 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b034">34</xref>
###xml 418 420 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b038">38</xref>
###xml 497 499 497 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b039">39</xref>
###xml 589 600 589 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila,</italic>
###xml 676 678 676 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b040">40</xref>
###xml 869 871 865 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b039">39</xref>
###xml 1227 1229 1219 1221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b039">39</xref>
###xml 1230 1232 1222 1224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b041">41</xref>
###xml 1248 1250 1240 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b033">33</xref>
###xml 1251 1253 1243 1245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b035">35</xref>
###xml 1337 1339 1329 1331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b041">41</xref>
###xml 1340 1342 1332 1334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b043">43</xref>
###xml 86 91 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 589 599 <span type="species:ncbi:7227">Drosophila</span>
Nuclear translocation of the two NFAT proteins that have been shown to play a role in HIV-1 gene transcription and replication in T cells, NFATp (also known as NFAT1 or NFATc2), and NFATc (also known as NFAT2 or NFATc1) [26-28,30] (reviewed in [36,37]), is regulated by the calcium-dependent phosphatase calcineurin, as is the case for NFAT3 (also known as NFATc4) and NFAT4 (also known as NFATc3) (reviewed in [33,34,38]). The most recently identified NFAT protein, NFAT5 (also known as TonEBP) [39], is the most evolutionarily divergent member of the NFAT family: NFAT5 has a homolog in Drosophila, while NFATp, NFATc, NFAT3, and NFAT4 are found exclusively in vertebrates [40]. NFAT5 was classified as an NFAT protein on the basis of its rel homology region domain, since it has greater sequence similarity with the NFAT protein family than with NF-kappaB proteins [39], but it is a unique member in many important respects. Specifically, (i) unlike the other NFAT proteins, NFAT5 binds DNA as an obligate dimer in a fashion similar to the NF-kappaB proteins; (ii) NFAT5 does not cooperate with the basic region leucine zipper proteins Fos and Jun in gene activation; and (iii) NFAT5 functions independently of calcinuerin [39,41] (reviewed in [33-35]). Finally, NFAT5 activity is regulated by osmotic stress and integrin activation [41-43], although the details of the upstream effects of these and other signal transduction pathways upon NFAT5 remain to be elucidated.
###end p 7
###begin p 8
###xml 64 69 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 308 313 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 397 402 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 416 421 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 430 459 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
###xml 461 464 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
###xml 588 593 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 618 623 <span type="species:ncbi:9606">human</span>
###xml 715 720 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 821 826 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1035 1040 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Here, we have identified a role for NFAT5 in the replication of HIV-1 in cells of the monocyte/macrophage lineage. We show that terminally differentiated macrophages have high constitutive levels of NFAT5 mRNA and protein, and that NFAT5 specifically and functionally binds to a site conserved in the LTR of HIV-1 subtypes B, C, and E. Strikingly, this unique NFAT5 site is conserved in all major HIV-1 subtypes, in HIV-2, and in simian immunodeficiency virus (SIV) from multiple primate species. By targeting NFAT5 expression with small interfering RNA (siRNA), we inhibit production of HIV-1 subtypes B, C, and E in human monocyte-derived macrophages (MDMs). Our results thus establish a pivotal role of NFAT5 in HIV-1 replication in a physiological monocyte/macrophage model system of infection. By demonstrating that HIV-1 replication can be inhibited in terminally differentiated macrophages by targeting the transcription factor NFAT5 through RNA interference, we illustrate a novel approach that may be harnessed in suppressing HIV-1 replication in this major viral reservoir.
###end p 8
###begin title 9
Materials and Methods
###end title 9
###begin title 10
Cell Culture
###end title 10
###begin p 11
###xml 10 12 10 12 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b044">44</xref>
###xml 742 744 739 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b045">45</xref>
###xml 947 954 944 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
HeLa-CD4 [44] cells were obtained from the United States National Institutes of Health AIDS Research and Reference Reagent Program () and were maintained in Dulbecco's modified Eagle's medium (DMEM) (Gibco, ) supplemented with 10% FCS, 50 U/ml penicillin, 50 mug/ml streptomycin, 2 mM L-glutamine, and 500 mug/ml G418. One day before experimental manipulation, cells were washed and incubated in medium without antibiotics and plated at ~70% confluence. THP-1 cells were obtained from the AIDS Research and Reference Reagent Program and were maintained in RPMI 1640 medium (Gibco) supplemented with 10% FCS, 50 U/ml penicillin, 50 mug /ml streptomycin, and 2 mM L-glutamine. Transfection of THP-1 cells was performed as described previously [45], and luciferase assays were performed according to the manufacturer's instructions (Dual Luciferase Reporter Assay System; Promega, ) using a Dynex luminometer (http://www.dynextechnologies.com), with Renilla luciferase (pRL-TK) as an internal control.
###end p 11
###begin title 12
###xml 15 20 <span type="species:ncbi:9606">Human</span>
Preparation of Human MDMs
###end title 12
###begin p 13
###xml 228 229 228 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 484 485 477 478 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 316 321 <span type="species:ncbi:9606">human</span>
Human monocytes were isolated from buffy coats prepared from healthy volunteer donors. Peripheral blood mononuclear cells isolated by Ficoll-Hypaque (Pharmacia Corporation, ) density gradient centrifugation were seeded at 6 x 106/2 ml in 12-well plates in RPMI 1640 medium and supplemented with 10% heat-inactivated human AB serum (Nabi Biopharmaceuticals, ), 50 U/ml penicillin, 50 mug /ml streptomycin, and 2 mM L-glutamine. The cell cultures were incubated at 37 degreesC and 5% CO2 overnight, after which nonadherent cells were removed by repeated gentle washing with warm medium. The cells were further incubated for 4 d in fresh medium before manipulation. More than 95% of the adherent cells obtained with this technique were CD14+ macrophages.
###end p 13
###begin title 14
siRNA Target Sequences and Transfection of Cell Lines and MDMs
###end title 14
###begin p 15
###xml 345 346 345 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 942 947 <span type="species:ncbi:9606">human</span>
siRNAs were constructed (Ambion, ) to target sequences of NFAT5: NFAT5#1, 5'-CAACATGCCTGGAATTCAA-3' (nucleotides [nt] 335 to 353), and NFAT5#2, 5'-CCAGTTCCTACAATGATAA-3' (nt 3981 to 3999). As a control for nonspecific siRNA effects, we used siRNA targeting the green fluorescent protein (GFP), 5'-GGCTACGTCCAGGAGCGCACC-3'. HeLa-CD4 cells (1 x 104) were transfected in 24-well plates with cationic lipid complexes, prepared by incubating 200 nM of the indicated siRNA in 3 mul siPORT NeoFX transfection reagent (Ambion), prepared as recommended by the manufacturer, in a final volume of 500 mul DMEM containing 10% FCS. After 24 h of incubation, cells were washed and resuspended in fresh medium. MDMs were seeded in 12-well plates and were transfected with 1 muM siRNA in 4 mul of siPORT NeoFX transfection reagent (Ambion), prepared as recommended by the manufacturer, and added to the cells in a final volume of 750 mul RPMI containing 10% human serum. The cultures were incubated overnight and then washed and incubated in fresh medium.
###end p 15
###begin title 16
Viruses
###end title 16
###begin p 17
###xml 5 8 5 8 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bal</sub>
###xml 18 24 18 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">93TH64</sub>
###xml 98 101 98 101 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LAI</sub>
###xml 111 117 111 117 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">98IN22</sub>
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 13 16 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 93 96 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 106 109 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV-1Bal and HIV-193TH64 were obtained from the AIDS Research and Reference Reagent Program. HIV-1LAI and HIV-198IN22 were obtained from the Centralised Facility for AIDS Reagents (), United Kingdom National Institute for Biological Standards and Control. High titer of virus stock was prepared by infection of a pool of phytohemagglutinin (Sigma, ) and IL-2-stimulated (AIDS Research and Reference Reagent Program) normal donor peripheral blood mononuclear cells with each virus for approximately 2 wk. Supernatants were aliquoted and stored at -70 degreesC.
###end p 17
###begin title 18
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Infection
###end title 18
###begin p 19
###xml 42 44 42 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 53 56 53 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LAI</sub>
###xml 464 466 464 466 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 475 478 475 478 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bal</sub>
###xml 491 493 491 493 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 502 508 502 508 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">98IN22</sub>
###xml 517 523 517 523 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">93TH64</sub>
###xml 48 51 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 359 364 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 470 473 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 497 500 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 512 515 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HeLa-CD4 cells were infected with 100 TCID50 of HIV-1LAI in 1 ml of medium. The cells were incubated overnight, after which they were washed and 1 ml fresh medium was added to each culture. After viral challenge, the cells were analyzed for p24 expression by flow cytometry and real-time PCR. Cell-free viral production was measured in supernatants using the HIV-1 p24 ELISA (enzyme-linked immunosorbent assay) kit (Perkin Elmer, ). MDMs were infected with 50 TCID50 of HIV-1Bal, or 100 TCID50 of HIV-198IN22 or HIV-193TH64 in 1 ml of medium. The cells were incubated for 24 h, after which they were washed and fresh medium was added. Supernatants were collected at different intervals and kept frozen at -70 degreesC for further analysis.
###end p 19
###begin title 20
Flow Cytometry
###end title 20
###begin p 21
###xml 480 482 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b046">46</xref>
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Uninfected cells or cells infected with HIV-1 were washed with HBSS, and fixed and permeabilized using the Fix and Perm kit from Caltag Laboratories (). The cells were stained with p24-RD1 conjugate (Beckman Coulter, ). Intracellular NFAT5 levels were determined using NFAT5 antibody (Oncogene Research Products, ) labeled with phycoerythrin and analyzed by flow cytometry on a FACSCalibur instrument with CellQuest software (Becton Dickinson, ) according to standard techniques [46].
###end p 21
###begin title 22
Quantitative PCR
###end title 22
###begin p 23
###xml 10 15 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
NFAT5 and HIV-1 expression level was determined by real-time PCR using SYBR green (Applied Biosystems, ). The reaction conditions were 95 degreesC for 10 min to activate the DNA polymers followed by 40 cycles of 95 degreesC for 20 s and 60.5 degreesC for 1 min. The results were normalized using beta-actin as an internal control.
###end p 23
###begin title 24
LTR Molecular Clone Construction
###end title 24
###begin p 25
###xml 122 125 122 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LAI</sub>
###xml 132 135 132 135 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BAL</sub>
###xml 154 160 154 160 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">98IN22</sub>
###xml 167 173 167 173 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">98CH01</sub>
###xml 192 198 192 198 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">93TH64</sub>
###xml 209 213 209 213 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KR25</sub>
###xml 377 380 377 380 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LAI</sub>
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b047">47</xref>
###xml 117 120 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 127 130 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 149 152 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 162 165 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 187 190 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 204 207 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 372 375 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
LTR molecular clones were constructed by inserting -208 to +64 nt relative to the transcriptional initiation site of HIV-1LAI, HIV-1BAL (B subtype), HIV-198IN22, HIV-198CH01 (C subtype), HIV-193TH64, and HIV-1KR25 (E subtype) into the pGL3 vector (Promega, ) using Xho I and Hind III restriction enzyme sites. Sequences were aligned and analyzed by using ClustalW (). The HIV-1LAI NFAT5 mutant (N5-Mut) was created by using standard PCR-based mutagenesis methods [47].
###end p 25
###begin title 26
DNase I Footprinting and Electrophoretic Mobility Shift Assay
###end title 26
###begin p 27
###xml 250 253 246 249 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LAI</sub>
###xml 264 270 260 266 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">98IN22</sub>
###xml 285 291 281 287 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">93TH64</sub>
###xml 315 322 311 318 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">[&#8722;32 P]</sup>
###xml 804 811 796 803 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">[&#8722;32 P]</sup>
###xml 829 831 821 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b048">48</xref>
###xml 900 909 892 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat-0020130-sg001">Figure S1</xref>
###xml 24 29 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 217 222 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 245 248 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 259 262 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 280 283 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
DNase I footprinting of HIV-1 LTR fragments was performed using recombinant NF-kappaB (p50/p65), NFATp (generous gifts from D. Thanos), and NFAT5 (a generous gift from A. Rao). Briefly, the -208 to +64-nt fragment of HIV-1 LTRs from subtypes B (HIV-1LAI), C (HIV-198IN22), and E (HIV-193TH64) were end-labeled with [-32 P]ATP using T4 polynucleotide kinase and incubated with increasing amounts of recombinant proteins. After 30 min of incubation, the samples were digested with 0.3 units of DNase I for exactly 1 min, resolved on an 8% denaturing polyacrylamide gel, and exposed overnight on film. In the electrophoretic mobility shift assay (EMSA) experiment with recombinant proteins, we used the NF-kappaB, NFATp, and NFAT5 recombinant proteins described above with oligonucleotides end-labeled with [-32 P]ATP as described [48]. For the EMSA with nuclear extracts from unstimulated THP-1 cells (Figure S1), the wild-type LTR oligonucleotide was used along with a specific anti-NFAT5 antibody (anti-NFAT5; Santa Cruz Biotechnology, ) or a control antibody (anti-Ig control, Santa Cruz Biotechnology).
###end p 27
###begin title 28
Statistical Analysis
###end title 28
###begin p 29
###xml 50 51 50 51 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</underline>
###xml 133 134 133 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 182 183 182 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Where applicable, results are expressed as a mean +SEM, and comparison between two groups was performed using the unpaired Student's t-test with the aid of Microsoft Excel software. p < 0.05 was considered significant.
###end p 29
###begin title 30
Results
###end title 30
###begin title 31
###xml 50 55 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Isolation and Sequence Analysis of Representative HIV-1 Subtype B, C, and E LTRs
###end title 31
###begin p 32
###xml 164 170 164 170 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">98IN22</sub>
###xml 187 191 187 191 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CH01</sub>
###xml 212 216 212 216 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KR25</sub>
###xml 237 243 237 243 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">93TH64</sub>
###xml 457 460 457 460 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BAL</sub>
###xml 470 473 470 473 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LAI</sub>
###xml 475 483 475 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g001">Figure 1</xref>
###xml 561 563 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b039">39</xref>
###xml 847 855 835 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g001">Figure 1</xref>
###xml 1010 1012 998 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b017">17</xref>
###xml 1013 1015 1001 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b027">27</xref>
###xml 1016 1018 1004 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b030">30</xref>
###xml 29 34 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 150 155 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 159 162 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 182 185 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 207 210 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 232 235 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 452 455 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 465 468 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 609 614 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 982 987 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To examine the regulation of HIV-1 subtypes by NFAT proteins, we first cloned and sequenced the LTR region (-208 to +64 nt) of representative primary HIV-1 C (HIV-198IN22, India and HIV-1CH01, China) and E (HIV-1KR25, Cambodia) and HIV-193TH64 (Thailand)) isolates. We analyzed at least ten clones from each isolate, determined the dominant sequences, and compared these results with LTR sequences that we cloned from the lab-adapted B subtype strains HIV-1BAL and HIV-1LAI (Figure 1). Strikingly, we found an NFAT5 consensus binding motif (5'-RNRNNTTTCCA-3') [39] that was completely conserved in all of the HIV-1 isolates examined. It overlaps the NF-kappaB site proximal to the start site of transcription in the subtype B isolates, the single NF-kappaB site in the subtype E isolates, and the central NF-kappaB site in the subtype C isolates (Figure 1). We note that these NFAT5 binding motifs also coincide with NFATp/NFATc binding sites previously detected in the LTRs of the HIV-1 B, C, and E subtypes [17,27,30].
###end p 32
###begin title 33
###xml 54 59 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
NFAT5 Binds to a Conserved Element within the LTRs of HIV-1 Subtypes B, C, and E
###end title 33
###begin p 34
###xml 250 253 246 249 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LAI</sub>
###xml 264 268 260 264 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CH01</sub>
###xml 277 284 273 280 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">198IN22</sub>
###xml 299 305 295 301 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">93TH64</sub>
###xml 227 232 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 245 248 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 259 262 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 273 276 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 294 297 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
To establish the pattern of NFAT5 binding to B, C, and E LTRs, we next compared the binding of recombinant NF-kappaB p50/p65, NFATp, and NFAT5 proteins to the LTRs (-208 to +64 nt relative to the transcription start site) from HIV-1 subtypes B (HIV-1LAI), C (HIV-1CH01 and HIV-198IN22), and E (HIV-193TH64), using quantitative DNase I footprinting analysis.
###end p 34
###begin p 35
###xml 194 202 194 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g002">Figure 2</xref>
###xml 241 249 241 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g002">Figure 2</xref>
###xml 549 557 541 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g002">Figure 2</xref>
###xml 793 795 781 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b049">49</xref>
###xml 796 798 784 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b050">50</xref>
###xml 917 919 901 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b017">17</xref>
###xml 920 922 904 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b029">29</xref>
We detected binding of p50/p65 at the two consensus sites in the B subtype LTR and the single consensus site in the E subtype; furthermore, p50/p65 bound to these sites with similar affinities (Figure 2A, panels 1 and 3; also see summary in Figure 2B). Interestingly, although the C subtype has three putative NF-kappaB binding motifs and the B subtype has two, approximately the same number of nucleotides is protected from DNase cleavage using the C and B LTRs, since binding of p50/p65 does not extend to the 3' kappaB site in the subtype C LTR (Figure 2B). The lack of binding of p50/p65 to the 3' site in the C subtypes can be ascribed to the presence of a thymine or cytosine in place of the purine that is typically in the fourth position of most NF-kappaB binding motifs (reviewed in [49,50]). We note that a cytosine has been observed in the fourth position of putative NF-kappaB motifs in other C isolates [17,29].
###end p 35
###begin p 36
###xml 34 36 34 36 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b017">17</xref>
###xml 37 39 37 39 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b029">29</xref>
###xml 40 42 40 42 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b051">51</xref>
###xml 126 134 122 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g002">Figure 2</xref>
###xml 140 141 136 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g002">2</xref>
###xml 420 428 416 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g002">Figure 2</xref>
###xml 674 676 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b028">28</xref>
###xml 677 679 661 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b052">52</xref>
###xml 771 779 755 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g002">Figure 2</xref>
###xml 1217 1225 1189 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g002">Figure 2</xref>
Consistent with previous reports [17,29,51], NFATp binds to sequences that overlap the NF-kappaB sites of the three subtypes (Figure 2A and 2B). In contrast to our results with p50/p65, the number of nucleotides protected by NFATp in each of the isolates is approximately the same, although NFATp exhibits the lowest relative affinity for the E subtype. This can be explained by further inspection of the LTR sequences (Figure 2B). The B and C subtypes contain two identical copies of NF-kappaB sites (both kappaB sites in B and the 5' and central kappaB sites in C); previous studies based on the B subtype LTR sequence have shown that NFATp binds as a dimer to this site [28,52]. These sites are 9-bp (base pair) inverted repeats of GGA core motifs (bold black font in Figure 2B), a consensus sequence that preferentially binds the NFATp dimer (J. Falvo, C. Lin, A. Tsytsykova, P. Hwang, D. Thanos, et al., unpublished data); this pattern does not appear in the 3' NF-kappaB-like site in the C subtype, which fails to bind NFATp or NF-kappaB p50/p65. The E subtype LTR has one copy of the conserved NF-kappaB site and an 8-bp inverted repeat of the GGA core motif (see dotted line boxed sequences and green font in Figure 2B), which is not optimal spacing for NFATp dimer binding (J. Falvo, C. Lin, A. Tsytsykova, P. Hwang, D. Thanos, et al., unpublished data).
###end p 36
###begin p 37
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b039">39</xref>
###xml 238 246 234 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g002">Figure 2</xref>
###xml 350 358 346 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g002">Figure 2</xref>
###xml 397 405 393 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g002">Figure 2</xref>
###xml 456 464 452 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g002">Figure 2</xref>
###xml 551 552 543 544 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</underline>
###xml 665 666 653 654 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</underline>
###xml 834 842 818 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g002">Figure 2</xref>
We next investigated whether NFAT5 could bind to the three LTRs, given that they contain a consensus NFAT5 binding site, 5'-RNRNNTTTCCA-3' [39], overlapping the NF-kappaB/NFATp dimer binding site proximal to the transcription start site (Figure 2A, panels 7-9). We found that NFAT5 protected an approximately equal number of nucleotides in each LTR (Figure 2B), footprinting at the B isolate LTR (Figure 2A, panel 7) more weakly than the C and E isolates (Figure 2A, panels 8 and 9). NFAT5 selectively binds the 3' NF-kappaB/NFATp motif (5'-GGGACTTTCCA-3', conserved in all subtypes examined) instead of the immediately upstream NF-kappaB/NFATp motif (5'-GGGACTTTCCG-3'), which varies by only a single base pair (underlined). Thus, NFAT5, unlike p50/p65, discriminates between the tandem NF-kappaB motifs of the B and C subtype LTRs (Figure 2B).
###end p 37
###begin p 38
###xml 386 388 382 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b047">47</xref>
###xml 389 391 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b053">53</xref>
###xml 392 394 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b055">55</xref>
###xml 145 150 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 416 421 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
These results thus define the binding site selectivity for NF-kappaB p50/p65, NFATp, and NFAT5 at the LTRs of representatives of three different HIV-1 subtypes. Different activators are able to bind in overlapping, yet distinct patterns within these enhancer regions, similar to inducer- and cell type-specific recruitment of different activators to the tumor necrosis factor promoter [47,53-55]. In the case of the HIV-1 LTR in three major viral subtypes, a single nucleotide difference, an adenine immediately 3' of the NF-kappaB sites, confers selective binding of NFAT5.
###end p 38
###begin title 39
###xml 46 51 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 53 58 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 64 67 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
The NFAT5 Binding Site Is Highly Conserved in HIV-1, HIV-2, and SIV LTRs
###end title 39
###begin p 40
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b017">17</xref>
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b056">56</xref>
###xml 199 202 199 202 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CPZ</sub>
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b057">57</xref>
###xml 545 553 541 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g003">Figure 3</xref>
###xml 32 35 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 90 95 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 137 142 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 152 157 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 168 171 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
###xml 228 233 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We next examined the Los Alamos HIV Sequence Database () for LTRs from representatives of HIV-1 Group M (for main) subtypes A through G, HIV-1 Group O, HIV-2, and five SIV LTRs [17,56], including SIVCPZ, the closest relative to HIV-1 [57], to determine whether the NFAT5 binding site we had discovered was present in other viral subtypes and in SIVs. Remarkably, we found complete conservation of the NFAT5 binding motif, including the 3' adenine that confers selective NFAT5 binding over closely related NF-kappaB sites, in each of these LTRs (Figure 3).
###end p 40
###begin title 41
Specific Disruption of NFAT5 Binding Impairs LTR Activation
###end title 41
###begin p 42
###xml 301 304 293 296 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LAI</sub>
###xml 330 338 322 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g004">Figure 4</xref>
###xml 544 546 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b050">50</xref>
###xml 912 920 892 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g004">Figure 4</xref>
###xml 296 299 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
We next examined the functional impact of NFAT5 binding upon LTR-mediated activation of transcription. Inspection of the NF-kappaB/NFATp/NFAT5 shared binding element suggested that we could disrupt NFAT5 but not NF-kappaB binding by mutating two of the thymines to cytosines in this motif in the HIV-1LAI subtype B LTR (N5-Mut in Figure 4A); in fact, these mutations convert the site to a canonical NF-kappaB p50/p65 site that is found in the major histocompatibility complex class I H2-kappaB enhancer and other promoter regions (reviewed in [50]). An EMSA using the wild-type and NFAT5 (N5-Mut) mutant oligonucleotides confirmed that changing the CC dinucleotide to TT in the N5-Mut did indeed significantly inhibit NFAT5 binding without disrupting the binding of p50/p65. In fact, the binding of p50/p65 when the site was converted to the major histocompatibility complex class I H2-kappaB site was enhanced (Figure 4A).
###end p 42
###begin p 43
###xml 232 235 232 235 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LAI</sub>
###xml 631 640 631 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat-0020130-sg001">Figure S1</xref>
###xml 741 744 737 740 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LAI</sub>
###xml 782 783 778 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 793 801 789 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g004">Figure 4</xref>
###xml 926 929 918 921 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LAI</sub>
###xml 210 215 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 227 230 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 404 409 <span type="species:ncbi:9606">human</span>
###xml 736 739 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 921 924 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
We next were interested in determining whether this specific mutation of the NFAT5 binding site resulted in a change in LTR-mediated gene activation. We thus introduced the CC to TT change in the context of an HIV-1 B subtype (HIV-1LAI) LTR-luciferase reporter gene spanning -208 to +64 nt relative to the transcription start site, transfected the wild-type and NFAT-5 mutant LTR reporter genes into the human monocytic cell line THP-1, and measured LTR driven luciferase activity 36 h later. We note that NFAT5 is present in nuclear extracts from unstimulated THP-1 monocytic cells and binds to the wild-type LTR oligonucleotide (Figure S1). The NFAT5-specific mutation, which does not impact NF-kappaB binding to this site, inhibited HIV-1LAI LTR expression by approximately 65% (p < 0.01) (Figure 4B). These data thus provide a direct link between the binding of NFAT5 at the core NFAT5/NF-kappaB/NFATp element of the HIV-1LAI LTR and the ability of this LTR to activate transcription.
###end p 43
###begin title 44
###xml 33 38 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Blocking NFAT5 by siRNA Inhibits HIV-1 Production in HeLa-CD4 Cells
###end title 44
###begin p 45
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b048">48</xref>
###xml 198 206 198 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g005">Figure 5</xref>
###xml 212 213 212 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g005">5</xref>
###xml 294 297 294 297 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LAI</sub>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b046">46</xref>
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b058">58</xref>
###xml 614 622 614 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g005">Figure 5</xref>
###xml 649 657 649 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g005">Figure 5</xref>
###xml 919 920 919 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 970 978 970 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g005">Figure 5</xref>
###xml 1156 1164 1156 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g005">Figure 5</xref>
###xml 289 292 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 460 465 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Consistent with the findings above in monocytic THP-1 cells and with our previous studies in fibroblast cells [48], we also detected constitutive levels of NFAT5 mRNA and protein in HeLa-CD4 cells (Figure 5A and 5B). Notably, HeLa-CD4 cells can be infected with and sustain replication of HIV-1LAI and have been successfully used in studies employing RNA interference [46,58]. These cells thus allowed us to determine whether NFAT5 played a functional role in HIV-1 replication using RNA interference. We designed small interfering RNA (siRNA) directed against NFAT5 and used these to block NFAT5 mRNA expression (Figure 5A) and protein production (Figure 5B) in HeLa-CD4 cells. To confirm the specificity of NFAT5 RNA inhibition, we designed another distinct NFAT5-specific siRNA targeting a different exon of NFAT5. We performed four independent experiments and demonstrated that both siRNAs significantly inhibited (p < 0.01) NFAT5 mRNA expression in HeLa-CD4 cells (Figure 5A). We also investigated the impact of siRNA directed against NFAT5 upon NFAT5 protein production using intracellular staining for NFAT5. As shown in the experiment displayed in Figure 5B (which is representative of four independent experiments), NFAT5 protein expression was lower in the cells transfected with an NFAT5 siRNA than in those mock transfected or transfected with the GFP siRNA.
###end p 45
###begin p 46
###xml 149 152 149 152 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LAI</sub>
###xml 291 299 291 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g005">Figure 5</xref>
###xml 649 657 649 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g005">Figure 5</xref>
###xml 757 758 757 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 978 986 978 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g005">Figure 5</xref>
###xml 144 147 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 215 220 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We next transfected HeLa-CD4 cells with each of the two NFAT5-specific siRNAs or with GFP siRNA as a control. The cells were then infected with HIV-1LAI. At day 3 post-infection, we performed internal staining with HIV-1 p24-RD1 conjugated antibody and analyzed the cells by flow cytometry (Figure 5C). No reduction in intracellular virus level was observed when the cells were transfected with GFP siRNA as compared with mock-transfected cells. However, there were 33.3% and 36.27% reductions in intracellular p24 levels in cells transfected with these specific NFAT5 siRNAs relative to mock-transfected cells and cells transfected with GFP siRNA (Figure 5C). Furthermore, using a p24 ELISA assay, we demonstrated that virus replication was significantly (p < 0.04) reduced in the supernatants of cells transfected with either one of the specific NFAT5 siRNAs compared with virus replication in supernatants from cells that were transfected with GFP siRNA or mock transfected (Figure 5D).
###end p 46
###begin title 47
###xml 92 97 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
NFAT5 Is Expressed in Primary Macrophages and Plays an Important Role in the Replication of HIV-1 Subtypes B, C, and E in MDMs
###end title 47
###begin p 48
###xml 318 326 318 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g006">Figure 6</xref>
###xml 342 350 342 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g006">Figure 6</xref>
Given that macrophages are a major virus reservoir as infection progresses, we next determined whether NFAT5 is produced in terminally differentiated primary macrophages and whether it plays a role in virus replication. We generated MDMs from normal donor peripheral blood mononuclear cells and found that NFAT5 mRNA (Figure 6A) and protein (Figure 6B) are constitutively expressed in these cells.
###end p 48
###begin p 49
###xml 111 112 111 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 157 165 157 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g006">Figure 6</xref>
###xml 467 475 467 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g006">Figure 6</xref>
We performed five independent experiments and demonstrated that NFAT5 siRNA (NFAT5#1) significantly inhibited (p < 0.02) NFAT5 mRNA expression in MDM cells (Figure 6A). We note that the second specific NFAT5 siRNA behaved identically in two experiments where it was tested (unpublished data). We also investigated the impact of siRNA directed against NFAT5 upon NFAT5 protein production using intracellular staining for NFAT5. As shown in the experiment displayed in Figure 6B, (which is representative of five independent experiments), NFAT5 protein expression was lower in the cells transfected with an NFAT5 siRNA than in those mock transfected or transfected with GFP siRNA.
###end p 49
###begin p 50
###xml 113 116 113 116 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bal</sub>
###xml 316 324 316 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g006">Figure 6</xref>
###xml 108 111 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 228 233 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We next transfected MDMs with NFAT5 siRNA or GFP siRNA (control) and then 4 d later infected the cells with HIV-1Bal (B subtype) and monitored virus replication. At day 4 post-infection, we performed intracellular staining with HIV-1 p24-RD1 conjugated antibody and analyzed the cells by flow cytometry. As shown in Figure 6C, there was a 26.9% reduction in intracellular p24 levels in cells transfected with NFAT5 siRNA compared with the cells transfected with GFP siRNA-transfected cells.
###end p 50
###begin p 51
###xml 272 278 272 278 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">98IN22</sub>
###xml 297 303 297 303 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">93TH64</sub>
###xml 325 328 325 328 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bal</sub>
###xml 755 763 755 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g006">Figure 6</xref>
###xml 1074 1082 1074 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g006">Figure 6</xref>
###xml 114 119 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 267 270 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 292 295 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 320 323 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
MDMs also provided us the opportunity to test the effect of NFAT5 inhibition upon the replication of the M-tropic HIV-1 subtype C and E primary isolates. We therefore transfected MDMs with NFAT5 siRNA or GFP siRNA (control) and then 4 d later infected the cells with HIV-198IN22 (C subtype), HIV-193TH64 (E subtype), or HIV-1Bal (B subtype) and performed a p24 ELISA to determine free virus levels in MDM cultures infected with the three viruses in the presence or absence of NFAT5 siRNA over time. The p24 levels from MDMs infected with the representative B, C, and E isolates were inhibited in the cultures transfected with NFAT5 siRNA compared with the control cultures transfected with GFP siRNA or mock transfected over the period of time monitored (Figure 6D). On day 13 post-infection, we analyzed the inhibition caused by NFAT5 siRNA versus transfection with the GFP siRNA or mock transfection. We observed that for the subtype B, C, and E isolates, specific inhibition by knocking down NFAT5 was on average 1.9-, 2-, and 2.1-fold, respectively, at this time point (Figure 6D). We obtained similar results using each of the two specific siRNAs targeting two different exons of NFAT5 in all of the experiments in MDMs (unpublished data).
###end p 51
###begin p 52
###xml 143 149 143 149 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">98IN22</sub>
###xml 156 162 156 162 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">93TH64</sub>
###xml 172 175 172 175 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bal</sub>
###xml 28 33 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 138 141 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 151 154 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 167 170 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 547 552 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To verify that infection by HIV-1 itself was not causing an increase in NFAT5 mRNA levels, we infected MDMs with live or heat-inactivated HIV-198IN22, HIV-193TH64, or HIV-1Bal and measured NFAT5 levels by real-time PCR at 24 and 48 h after infection. There was no change in NFAT5 levels at either time point after infection of cells with live virus or incubation with heat inactivated viruses as compared with uninfected cells (unpublished data). Taken together, these results demonstrate that NFAT5 plays a significant role in the replication of HIV-1 from subtype B, C, and E isolates in primary differentiated macrophages.
###end p 52
###begin title 53
Discussion
###end title 53
###begin p 54
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b012">12</xref>
###xml 496 497 496 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b007">7</xref>
###xml 802 810 802 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g003">Figure 3</xref>
###xml 170 175 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 323 328 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 458 463 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 608 613 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 665 670 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 713 718 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 731 736 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 758 761 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
In this study, we have combined in vitro and ex vivo studies with sequence analysis approaches to reveal a new function for NFAT5 in the replication of major subtypes of HIV-1 in cells of the monocyte/macrophage lineage. Previous studies have demonstrated that a range of transcription factors can interact with the LTR of HIV-1 subtype B (reviewed in [12]), and it has been proposed that distinct sets of host factors may direct transcription driven by the HIV-1 LTR in T cells and macrophages [7]. Remarkably, the functional NFAT5 site, 5'-GGGACTTTCCA-3', that we have identified in the LTR of isolates of HIV-1 subtypes B, C, and E, is conserved not only across HIV-1 Group M subtypes A through G, but also in HIV-1 Group O and HIV-2 isolates, as well as SIV isolates from multiple primate species (Figure 3).
###end p 54
###begin p 55
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b017">17</xref>
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b056">56</xref>
###xml 348 356 344 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g002">Figure 2</xref>
###xml 572 580 564 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020130-g002">Figure 2</xref>
###xml 150 153 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 302 307 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The evolutionary pressure toward conservation of this NFAT5 site is particularly striking given the variability of LTR sequences between subtypes and HIV species [17,56], including the number and arrangement of transcription factor binding sites, as illustrated by the binding of NF-kappaB proteins to HIV-1 subtype B, C, and E LTRs in this study (Figure 2A). Furthermore, we have shown that a single nucleotide difference, a 3' adenine, between the NFAT5 site and an upstream NF-kappaB binding site, confers selective binding of NFAT5 to this conserved enhancer element (Figure 2).
###end p 55
###begin p 56
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b041">41</xref>
###xml 505 507 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b043">43</xref>
###xml 1033 1035 1033 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b059">59</xref>
###xml 1299 1301 1299 1301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b034">34</xref>
###xml 549 554 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 973 978 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1104 1109 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1581 1586 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
NFAT5 is unique among the NFAT proteins both in its DNA-binding properties and in the upstream signal transduction pathways that regulate its activity. Unlike the other NFAT family members, NFAT5 binds as an obligate dimer and does not act coordinately with Fos and Jun proteins. While the nuclear translocation of other NFAT proteins is tightly regulated by the calcium-dependent phosphatase calcinuerin, the activity of NFAT5 has been shown to be regulated by osmotic stress and integrin activation [41-43]. Our findings that NFAT5 is involved in HIV-1 replication in cells of the monocyte/macrophage lineage, as well as in a nonlymphoid model cell line, and that its functional DNA binding site is highly conserved, provide an initial insight into other potential upstream regulatory mechanisms that further distinguish the physiological role of this evolutionarily divergent NFAT protein from its calcineurin-responsive counterparts. It is interesting to note that the HIV-1 LTR can be activated by osmotic stress in HeLa cells [59]; thus, the upstream signaling pathways involved in NFAT5-dependent HIV-1 replication may overlap with those responsible for osmotic stress-induced transcription of NFAT5-dependent cellular genes. The features of these signaling pathways remain to be determined [34]. Working backward from this functional binding site may thus reveal critical, evolutionarily conserved mechanisms through which constitutive or activated signals are propagated from the cell membrane, resulting in NFAT5-dependent gene expression that is critical in maintaining HIV-1 replication in the monocyte/macrophage lineage.
###end p 56
###begin p 57
###xml 163 168 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 300 305 <span type="species:ncbi:9606">human</span>
###xml 418 423 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 496 501 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 534 539 <span type="species:ncbi:9606">human</span>
###xml 575 580 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 795 800 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Even though both NF-kappaB and NFAT proteins interact with the conserved NFAT5 site, our results have demonstrated a specific role for NFAT5 in the replication of HIV-1 in cells of the monocyte/macrophage lineage. We have established that NFAT5 mRNA and protein are constitutively present in primary human macrophages. Strikingly, replacement of the NFAT5 site with a canonical NF-kappaB site inhibits activity of the HIV-1 LTR, and direct inhibition of NFAT5 using siRNA inhibits replication of HIV-1 subtypes B, C, and E in primary human macrophages. By examining multiple HIV-1 subtypes, we have discovered a function for a binding site conserved across viral types and even across primate species; this finding, together with the importance of macrophages as a viral reservoir through which HIV-1 can persistently infect multiple tissues, underscores the potential of the NFAT5-LTR interaction as a therapeutic target to suppress virus replication and disease progression.
###end p 57
###begin title 58
Supporting Information
###end title 58
###begin title 59
NFAT5 Binds to the LTR in THP-1 Cells
###end title 59
###begin p 60
An EMSA with nuclear extracts from unstimulated THP-1 monocytic cells and the wild-type LTR oligonucleotide is shown. Reactions were untreated (-) or incubated with a specific anti-NFAT5 antibody (anti-NFAT5) or a control antibody (anti-Ig control). Note that the NFAT5-DNA complex (indicated by the arrow) is ablated by the anti-NFAT5 antibody.
###end p 60
###begin p 61
(1.0 MB TIF)
###end p 61
###begin p 62
Click here for additional data file.
###end p 62
###begin p 63
The authors would like to thank Dimitris Thanos for the generous gift of recombinant NF-kappaB and NFATp and Anjana Rao for the generous gift of NFAT5.
###end p 63
###begin title 64
Abbreviations
###end title 64
###begin p 65
base pair
###end p 65
###begin p 66
enzyme-linked immunosorbent assay
###end p 66
###begin p 67
electrophoretic mobility shift assay
###end p 67
###begin p 68
green fluorescent protein
###end p 68
###begin p 69
long terminal repeat
###end p 69
###begin p 70
monocyte-derived macrophage
###end p 70
###begin p 71
###xml 5 8 5 8 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LAI</sub>
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV-1LAI NFAT5 mutant
###end p 71
###begin p 72
nuclear factor kappaB
###end p 72
###begin p 73
nuclear factor of activated T cells
###end p 73
###begin p 74
nucleotides
###end p 74
###begin p 75
small interfering RNA
###end p 75
###begin p 76
###xml 0 29 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
simian immunodeficiency virus
###end p 76
###begin title 77
References
###end title 77
###begin article-title 78
###xml 72 77 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
###end article-title 78
###begin article-title 79
###xml 75 110 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy
###end article-title 79
###begin article-title 80
###xml 16 19 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Macrophages and HIV infection: Therapeutical approaches toward this strategic virus reservoir
###end article-title 80
###begin article-title 81
###xml 61 66 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The role of monocytes and macrophages in the pathogenesis of HIV-1 infection
###end article-title 81
###begin article-title 82
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV and cells of macrophage/dendritic lineage and other non-T cell reservoirs: New answers yield new questions
###end article-title 82
###begin article-title 83
###xml 34 39 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Pathogenesis of macrophage tropic HIV-1
###end article-title 83
###begin article-title 84
###xml 16 21 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Macrophages and HIV-1: Dangerous liaisons
###end article-title 84
###begin article-title 85
###xml 20 48 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Macrophages and the human immunodeficiency virus
###end article-title 85
###begin article-title 86
###xml 14 49 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors
###end article-title 86
###begin article-title 87
###xml 37 65 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Macrophages: A crucial reservoir for human immunodeficiency virus in the body
###end article-title 87
###begin article-title 88
###xml 48 55 <span type="species:ncbi:9606">patient</span>
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)
###end article-title 88
###begin article-title 89
###xml 69 74 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A compilation of cellular transcription factor interactions with the HIV-1 LTR
###end article-title 89
###begin article-title 90
Lentiviral LTR-directed expression, sequence variation, and disease pathogeneis
###end article-title 90
###begin article-title 91
###xml 56 61 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Accelerating the development and future availability of HIV-1 vaccines: Why, when, where, and how?
###end article-title 91
###begin article-title 92
###xml 50 78 <span type="species:ncbi:12721">human immunodeficiency virus</span>
###xml 80 83 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
A review of vaccine research and development: The human immunodeficiency virus (HIV)
###end article-title 92
###begin article-title 93
###xml 53 58 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000
###end article-title 93
###begin article-title 94
###xml 85 120 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G
###end article-title 94
###begin article-title 95
###xml 17 52 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Evolution of the human immunodeficiency virus type 1 long terminal repeat promoter by conversion of an NF-kappaB enhancer element into a GABP binding site
###end article-title 95
###begin article-title 96
###xml 51 86 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Elevated tumor necrosis factor-alpha activation of human immunodeficiency virus type 1 subtype C in Southern Africa is associated with an NF-kappaB enhancer gain-of-function
###end article-title 96
###begin article-title 97
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 subtypes have a distinct long terminal repeat that determines the replication rate in a host-cell-specific manner
###end article-title 97
###begin article-title 98
###xml 58 86 <span type="species:ncbi:12721">human immunodeficiency virus</span>
An inducible transcription factor activates expression of human immunodeficiency virus in T cells
###end article-title 98
###begin article-title 99
###xml 50 55 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 59 64 <span type="species:ncbi:9606">human</span>
Tumor necrosis factor stimulates transcription of HIV-1 in human T lymphocytes, independently and synergistically with mitogens
###end article-title 99
###begin article-title 100
###xml 61 66 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cellular transcription factors involved in the regulation of HIV-1 gene expression
###end article-title 100
###begin article-title 101
Hostile takeovers: Viral appropriation of the NF-kappaB pathway
###end article-title 101
###begin article-title 102
###xml 16 21 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells
###end article-title 102
###begin article-title 103
###xml 57 62 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells
###end article-title 103
###begin article-title 104
###xml 42 77 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Reciprocal modulatory interaction between human immunodeficiency virus type 1 Tat and transcription factor NFAT1
###end article-title 104
###begin article-title 105
###xml 50 55 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
T-cell activation leads to poor activation of the HIV-1 clade E long terminal repeat and weak association of nuclear factor-kappaB and NFAT with its enhancer region
###end article-title 105
###begin article-title 106
###xml 15 20 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 48 53 <span type="species:ncbi:9606">human</span>
NFAT1 enhances HIV-1 gene expression in primary human CD4 T cells
###end article-title 106
###begin article-title 107
###xml 83 88 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Nuclear factor of activated T cells is a driving force for preferential productive HIV-1 infection of CD45RO-expressing CD4+ T cells
###end article-title 107
###begin article-title 108
Isolation of the cyclosporin-sensitive T cell transcription factor NFATp
###end article-title 108
###begin article-title 109
Transcriptional regulation by calcium, calcineurin, and NFAT
###end article-title 109
###begin article-title 110
NFAT proteins: Key regulators of T-cell development and function
###end article-title 110
###begin article-title 111
NFAT and NF-kappaB factors-the distant relatives
###end article-title 111
###begin article-title 112
###xml 69 74 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Reciprocal regulation of the nuclear factor of activated T cells and HIV-1
###end article-title 112
###begin article-title 113
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1, NFAT, and cyclosporin: Immunosuppression for the immunosuppressed?
###end article-title 113
###begin article-title 114
NFAT signaling: Choreographing the social lives of cells
###end article-title 114
###begin article-title 115
NFAT5, a constitutively nuclear NFAT protein that does not cooperate with Fos and Jun
###end article-title 115
###begin article-title 116
Evolutionary relationships among Rel domains indicate functional diversification by recombination
###end article-title 116
###begin article-title 117
Bridging the NFAT and NF-kappaB families: NFAT5 dimerization regulates cytokine gene transcription in response to osmotic stress
###end article-title 117
###begin article-title 118
Tonicity-responsive enhancer binding protein, a rel-like protein that stimulates transcription in response to hypertonicity
###end article-title 118
###begin article-title 119
The role of NFAT transcription factors in integrin-mediated carcinoma invasion
###end article-title 119
###begin article-title 120
###xml 24 34 <span type="species:ncbi:11676">AIDS virus</span>
The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain
###end article-title 120
###begin article-title 121
###xml 37 40 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Transactivator of transcription from HIV type 1 subtype E selectively inhibits TNF gene expression via interference with chromatin remodeling of the TNF locus
###end article-title 121
###begin article-title 122
###xml 108 111 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV
###end article-title 122
###begin article-title 123
Inducer-specific enhanceosome formation controls tumor necrosis factor alpha gene expression in T lymphocytes
###end article-title 123
###begin article-title 124
NFAT5 binds to the TNF promoter distinctly from NFATp, c, 3 and 4, and activates TNF transcription during hypertonic stress alone
###end article-title 124
###begin article-title 125
Interactions of NF-kappaB with chromatin: The art of being at the right place at the right time
###end article-title 125
###begin article-title 126
###xml 20 32 <span type="species:ncbi:9606">Participants</span>
NF-kappa B and Rel: Participants in a multiform transcriptional regulatory system
###end article-title 126
###begin article-title 127
###xml 53 88 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Divergent transcriptional regulation among expanding human immunodeficiency virus type 1 subtypes
###end article-title 127
###begin article-title 128
###xml 43 48 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Structure of NFAT1 bound as a dimer to the HIV-1 LTR kappa B element
###end article-title 128
###begin article-title 129
Stimulus-specific assembly of enhancer complexes on the tumor necrosis factor alpha gene promoter
###end article-title 129
###begin article-title 130
A lipopolysaccharide-specific enhancer complex involving ets, elk-1, sp1, and CREB binding protein and p300 is recruited to the tumor necrosis factor alpha promoter in vivo
###end article-title 130
###begin article-title 131
Nuclear factor of activated T cells transcription factor NFATp controls superantigen-induced lethal shock
###end article-title 131
###begin article-title 132
###xml 0 10 <span type="species:ncbi:9598">Chimpanzee</span>
###xml 50 55 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Chimpanzee reservoirs of pandemic and nonpandemic HIV-1
###end article-title 132
###begin article-title 133
###xml 41 76 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages
###end article-title 133
###begin article-title 134
###xml 18 23 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Activation of the HIV-1 long terminal repeat by cytokines and environmental stress requires an active CSBP/p38 MAP kinase
###end article-title 134
###begin article-title 135
Structure of a TonEBP-DNA complex reveals DNA encircled by a transcription factor
###end article-title 135
###begin title 136
Figures and Tables
###end title 136
###begin title 137
Alignment of LTR Promoter and Enhancer Sequences in Representative Isolates of Subtypes B, C, and E
###end title 137
###begin p 138
Sequence variation within the NF-kappabeta/NFATp, SP1, and TATA box regions that distinguish the C and E subtypes from the B subtype are indicated in the boxes. Sequences were aligned and analyzed by using ClustalW ().
###end p 138
###begin title 139
###xml 47 52 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
NFAT5 Binds Distinctly to a Motif Conserved in HIV-1 Subtype B, C, and E LTR Promoter Regions
###end title 139
###begin p 140
###xml 589 591 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b060">60</xref>
###xml 85 90 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 123 128 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 209 214 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(A) NF-kappabeta, NFATp, and NFAT5 bind to distinct and overlapping sequences in the HIV-1 LTR enhancer/promoter region of HIV-1 subtypes B, C, and E. Quantitative DNase I footprinting analysis is shown using HIV-1 LTR fragments (-208 to +64 nt relative to the transcription start site) from representative subtype B, C, and E viral isolates and increasing concentrations of recombinant NF-kappaB (p50/p65), NFATp (20 ng, 100 ng, 400 ng, and 20 mug), or NFAT5 (10 mug, 50 mug, 200 mug, and 1 mg) as shown. The low DNA-binding affinity of NFAT5 relative to NFATp has been noted previously [60]. The regions that are protected from DNase cleavage by the binding of NF-kappaB, NFATp, and NFAT5 are indicated with bars. We note that in the case of NFAT5, distinct cleavage patterns (including a hypersensitive site 5' to the region of DNase I protection) are evident at 200 mug.
###end p 140
###begin p 141
###xml 96 101 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(B) Summary of DNase footprinting results with NF-kappabeta, NFATp, and NFAT5, and alignment of HIV-1 LTR nucleotide sequences from representative isolates from subtypes B, C, and E. The diagram illustrates the sequences protected from DNase cleavage by the binding of NF-kappabeta (blue), NFATp (green), and NFAT5 (red). The NF-kappabeta, NFATp, and NFAT5 binding sites are boxed. The broken boxes indicate sites that have sequence similarity to NF-kappabeta, NFATp, and NFAT5 sites, but which do not bind the proteins in the footprinting assay displayed in (A). The GGA repeats in the NFATp core dimer binding region are shown in bold.
###end p 141
###begin title 142
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 47 52 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 58 61 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
The NFAT5 Binding Motif Is Conserved in HIV-1, HIV-2, and SIV LTRs
###end title 142
###begin p 143
###xml 177 180 177 180 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LAI</sub>
###xml 440 442 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b017">17</xref>
###xml 443 445 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b056">56</xref>
###xml 21 26 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 60 65 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 85 90 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 104 107 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
###xml 172 175 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 414 417 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 465 470 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Sequence analysis of HIV-1 Group M subtypes A through G and HIV-1 Group O as well as HIV-2 and selected SIV LTR enhancer/promoter regions. Numbering is based on B subtype (HIV-1LAI) sequences. The conserved NFAT5 binding motif is highlighted in yellow; the sequence corresponding to the canonical NF-kappaB site is in red, and the unique 3' terminal adenine is in blue. Sequences were obtained from the Los Alamos HIV Sequence Database () [17,56] and aligned using HIV-1 subtype B sequences spanning -123 to -68 nt relative to the viral transcription start site as a reference.
###end p 143
###begin title 144
Specific Disruption of NFAT5 Binding Impairs LTR-Reporter Gene Activity in Monocytic THP-1 Cells
###end title 144
###begin p 145
###xml 219 222 201 204 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LAI</sub>
###xml 214 217 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
(A) Disruption of NFAT5 binding does not impair NF-kappabeta (p50/p65) binding. An EMSA is shown using recombinant NFAT5 and NF-kappaB proteins with an oligonucleotide matching the NFAT5/NF-kappabeta site from the HIV-1LAI (wild-type [WT]) or an oligonucleotide with a mutation in the nt predicted to be required for NFAT5 binding (N5-Mut), but not NF-kappaB binding (shown at the bottom of the figure).
###end p 145
###begin p 146
###xml 66 69 66 69 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LAI</sub>
###xml 113 116 113 116 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LAI</sub>
###xml 231 234 231 234 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LAI</sub>
###xml 339 346 339 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 531 532 531 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 61 64 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 108 111 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 226 229 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
(B) Mutation of the NFAT5 binding site significantly reduces HIV-1LAI LTR reporter activity in THP-1 cells. HIV-1LAI LTR-Luc reporter constructs that contained -208 to +64 nt relative to the transcriptional initiation site of HIV-1LAI, and that were isogenic except for the specific N5 mutation, were transfected into THP-1 cells with the Renilla luciferase (pRL-TK) control plasmid. Luciferase activity was determined 26 h later. The LTR mutation, which abolishes NFAT5 binding to the promoter/enhancer region, significantly (**, p < 0.01) suppressed LTR-dependent activity of transcription compared with WT in THP-1 cells.
###end p 146
###begin title 147
###xml 44 49 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
NFAT5 Plays an Important Functional Role in HIV-1 Replication in HeLa-CD4 Cells
###end title 147
###begin p 148
###xml 166 167 166 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 515 517 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b046">46</xref>
###xml 518 520 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020130-b058">58</xref>
###xml 498 501 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
(A) Real-time PCR showing that HeLa-CD4 cells constitutively express NFAT5 mRNA. Using siRNA-targeting NFAT5, we were able to reduce NFAT5 mRNA levels significantly (p < 0.01) compared with that of GFP siRNA or mock-transfected cells. To confirm that NFAT5 knockdown was specific, we used two NFAT5 siRNAs (NFAT5#1 and NFAT#2) targeting two different exons of the NFAT5 gene. We chose the sequence siRNA to GFP because this sequence has been validated and shown to have no nonspecific effects upon HIV replication [46,58]. Results show the average of four independent experiments.
###end p 148
###begin p 149
(B) Flow cytomety analysis of intracellular NFAT5 levels in HeLa-CD4 cells. A representative experiment of a flow cytometry analysis using a monoclonal antibody to NFAT5 demonstrated that intracellular NFAT5 protein levels were lower in the cells transfected with NFAT5 siRNA than those that were transfected with GFP siRNA or mock transfected. The experiment is representative of four independent experiments.
###end p 149
###begin p 150
###xml 64 67 64 67 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LAI</sub>
###xml 59 62 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 107 112 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(C) Flow cytometry analysis of intracellular p24 levels in HIV-1LAI infected HeLa-CD4 cells. Intracellular HIV-1 levels were determined using a p24-RD1 conjugate in a representative experiment. Three days following virus infection, intracellular p24 was lower in cells transfected with NFAT5 siRNA targeting two different exons of NFAT5 (NFAT5#1 and NFAT5#2; 33.3% and 36.27% inhibition, respectively) than in cells transfected with a GFP control siRNA or mock transfected. This experiment is representative of four independent experiments.
###end p 150
###begin p 151
###xml 53 56 53 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LAI</sub>
###xml 143 144 143 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 48 51 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 82 87 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(D) Cell-free p24 production in supernatants of HIV-1LAI infected HeLa-CD4 cells. HIV-1 replication as assessed by p24 ELISA is significantly (p < 0.04) lower in cellular cultures transfected with NFAT5 siRNA targeting two different exons of NFAT5 (NFAT5#1 and NFAT5#2) than in cells mock transfected or transfected with the GFP control siRNA.
###end p 151
###begin title 152
###xml 72 77 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
MDMs Constitutively Express NFAT5, Which Is Required for Replication of HIV-1 Representative Isolates from Subtypes B, C, and E
###end title 152
###begin p 153
###xml 237 238 237 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 37 42 <span type="species:ncbi:9606">human</span>
(A) NFAT5 expression was detected in human MDMs using real-time PCR. NFAT5 mRNA expression was significantly inhibited 6 d after transfection with NFAT5 siRNA (NFAT5#1) compared with cells transfected with GFP siRNA or mock transfected (p < 0.02).
###end p 153
###begin p 154
(B) Flow cytomety analysis of intracellular NFAT5 levels in MDMs. A representative experiment is shown of a flow cytometry analysis of MDM using a monoclonal antibody to NFAT5. Intracellular NFAT5 protein levels were lower in the cells transfected with NFAT5 siRNA than in those transfected with GFP siRNA or those mock transfected. The experiment is representative of five independent experiments.
###end p 154
###begin p 155
###xml 64 67 64 67 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BAL</sub>
###xml 139 142 139 142 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bal</sub>
###xml 59 62 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 134 137 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
(C) Flow cytometry analysis of intracellular p24 levels in HIV-1BAL-infected MDMs. Mock- or siRNA-transfected MDMs were infected with HIV-1Bal, and intracellular p24 levels were determined on day 4 post-infection with flow cytometry using the p24-RD1 conjugated antibody. Intracellular virus levels were 26.9% lower in the cells transfected with NFAT5 siRNA than in GFP siRNA-transfected cells.
###end p 155
###begin p 156
###xml 229 232 229 232 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BAL</sub>
###xml 243 249 243 249 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">98IN22</sub>
###xml 263 269 263 269 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">93TH64</sub>
###xml 658 661 658 661 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BAL</sub>
###xml 685 691 685 691 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">98IN22</sub>
###xml 721 727 721 727 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">93TH64</sub>
###xml 51 56 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 224 227 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 238 241 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 258 261 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 653 656 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 680 683 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 716 719 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
(D) Knockdown of NFAT5 RNA inhibits replication of HIV-1 representative isolates from subtypes B, C, and E. Cell-free virus replication was determined by p24 ELISA at day 3, 6, 9, and 13 post-infection of MDMs by subtype B (HIV-1BAL), C (HIV-198IN22), or E (HIV-193TH64) viruses as indicated. Free virus levels were lower in the cells transfected with NFAT5 siRNA compared with the cells transfected with GFP siRNA (control) in cellular supernatants at all the time points monitored and indicated in the figure. Notably, on day 13 post-infection, inhibition of free virus levels in the NFAT5 siRNA-transfected cultures was on average 1.9-fold lower for HIV-1BAL, 2-fold lower for HIV-198IN22, and 2.1-fold lower for HIV-193TH64 compared with GFP siRNA-transfected cultures.
###end p 156
###begin p 157
currency Current address: CBR Institute for Biomedical Research, Harvard Medical School, Boston, Massachusetts, United States of America
###end p 157
###begin p 158
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests.</bold>
Competing interests. The authors have declared that no competing interests exist.
###end p 158
###begin p 159
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. SR designed the experiments, interpreted the data, isolated all of the viruses, and performed siRNA and plasmid transfection and virus infection experiments. AVT performed in vitro footprinting analysis and EMSA. SKL designed the siRNA primers and participated in the FACS experiments. RR performed the RT-PCR analyses. JVF participated in interpretation of data and preparation of the manuscript. JL and PS participated in the design of experiments and interpretation of data. AG actively participated in the design of experiments, interpretation of data, and preparation of the manuscript.
###end p 159
###begin p 160
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding.</bold>
Funding. This work was supported by grants from the US National Institutes of Health to AEG (R21AI060433-01 and AI065285-01A1) and PS (AI065342), and the Harvard Center for AIDS Research (P30 A060354) and the Campbell Foundation to SR.
###end p 160

